WO2006137513A1 - 表皮細胞分化及び角化促進剤、並びに表皮角化促進用機能性飲食品 - Google Patents
表皮細胞分化及び角化促進剤、並びに表皮角化促進用機能性飲食品 Download PDFInfo
- Publication number
- WO2006137513A1 WO2006137513A1 PCT/JP2006/312578 JP2006312578W WO2006137513A1 WO 2006137513 A1 WO2006137513 A1 WO 2006137513A1 JP 2006312578 W JP2006312578 W JP 2006312578W WO 2006137513 A1 WO2006137513 A1 WO 2006137513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- keratinization
- promoter
- fermented milk
- promoting
- differentiation
- Prior art date
Links
- 230000003780 keratinization Effects 0.000 title claims abstract description 44
- 235000013376 functional food Nutrition 0.000 title claims abstract description 19
- 230000004069 differentiation Effects 0.000 title abstract description 9
- 235000020510 functional beverage Nutrition 0.000 title abstract description 8
- 210000002615 epidermis Anatomy 0.000 title description 6
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 42
- 239000005862 Whey Substances 0.000 claims abstract description 40
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 40
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 40
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000001737 promoting effect Effects 0.000 claims abstract description 23
- 235000013336 milk Nutrition 0.000 claims abstract description 17
- 239000008267 milk Substances 0.000 claims abstract description 17
- 210000004080 milk Anatomy 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 13
- 239000004310 lactic acid Substances 0.000 claims abstract description 13
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 8
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 8
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 8
- 210000001339 epidermal cell Anatomy 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 16
- 230000024245 cell differentiation Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 description 15
- 102000007236 involucrin Human genes 0.000 description 9
- 108010033564 involucrin Proteins 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 230000035622 drinking Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 2
- 108010065038 Keratin-10 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
- A23C21/026—Whey; Whey preparations containing, or treated with, microorganisms or enzymes containing, or treated only with, lactic acid producing bacteria, bifidobacteria or propionic acid bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/195—Proteins from microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- Epidermal cell differentiation and keratinization promoter and functional food and drink for promoting keratinization
- the present invention promotes normal keratinization of the epidermis by promoting differentiation of epidermal cells in dry skin, rough skin, and various skin disease groups accompanied by keratinization such as psoriasis and dry skin. Furthermore, the present invention relates to an agent for promoting epidermal cell differentiation and keratinization, which is effective for normalizing various skin troubles, and a functional food and drink for promoting keratinization.
- epidermis in the outermost layer of skin tissue is an area that is directly exposed to the outside world and easily damaged by various physical and chemical irritation. For this reason, epidermal cells born in the basal layer at the deepest part of the epidermis migrate outward and are constantly replaced with new cells. This is called epidermal turnover. In this process, epidermal cells undergo basal cells, spinous cells, condylar cells, and keratinocytes, and then undergo a four-stage separation process. It will fall off the surface. Usually, it takes about 14 days to keratinize the basal cells into keratinocytes and about 14 days to keratinocytes become desquamated and desquamated, a total of 4-6 weeks. .
- Healthy keratinocytes of the epidermis are stratified into about 15 layers, forming a stratum corneum.
- This stratum corneum has an excellent barrier function and plays an important role in the defense of the body, such as preventing the evaporation of moisture in the body, preventing the invasion of foreign substances such as foreign antigens, and the transmission of external stimuli into the body.
- various skin diseases such as atopic dermatitis, psoriasis, and psoriasis
- the formation of a healthy stratum corneum is impeded. It is thought that it causes moisture transpiration, invasion of foreign substances, and transmission of external stimuli to the body, leading to dryness of the skin and various skin diseases.
- the stratum corneum becomes thick, causing a rough skin condition such as premature skin stiffness and stiffness. Abnormal keratinization is regarded as a problem.
- Patent Document 1 Japanese Patent No. 3227378
- An object of the present invention is to provide a functional drink and food that can obtain a normal keratinization promoting action of skin by oral ingestion, and an epidermal cell differentiation and keratinization promoter used in the functional food and drink. .
- an epidermal cell differentiation and keratinization promoting agent comprising fermented milk whey obtained by fermenting milk with bacterial cells containing lactic acid bacteria as an active ingredient.
- the functional food-drinks for the epidermal keratinization promotion containing the said epidermal cell differentiation and keratinization promoter are provided.
- the epidermal cell differentiation and keratinization promoting agent and the functional food and drink for promoting epidermal keratinization of the present invention include fermented milk whey, whose safety has already been confirmed by oral ingestion, and is therefore safe. It has an excellent oral keratinization-promoting effect and can be used to prevent dry skin and rough skin caused by seasonal and climate changes due to continuous ingestion, etc., or atopic dermatitis, psoriasis and psoriasis. Improvement of various symptoms of various skin diseases characterized by full keratinization Expect fruit.
- FIG. 1 is a copy of a photomicrograph showing the protein expression analysis result of the mitotic marker performed in Example 1.
- FIG. 2 is a graph showing the effect of promoting the expression of KeratinlO at the mRNA level performed in Example 1.
- FIG. 3 is a graph showing the effect of promoting the expression of Involucrin at the mRNA level performed in Example 1.
- FIG. 4 is a graph showing the change over time in the expression level of the kinematic marker (KeratinlO) performed in Example 1.
- FIG. 5 is a graph showing the change over time in the expression level of the differentiation marker (Involucrin) performed in Example 1.
- FIG. 6 is a graph showing the results of the cytotoxicity test conducted in Example 1.
- the epidermal cell differentiation and keratinization promoter of the present invention contains fermented milk whey obtained by fermenting milk with microbial cells containing lactic acid bacteria as an active ingredient.
- lactic acid bacterium examples include lactic acid bacteria belonging to the genus Streptococcus, Ratatococcus, Lactobacillus, Bifidopacteria, etc., and the genus Lactobacillus is preferred. Specifically, for example, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus helveticus, Lactobacillus s casei, Lactobacillus acidophilus -Lactobacillus acidophilus- Examples include Lactobacillus fermentum, and Lactobacillus helveticus can be particularly preferably used.
- the Lactobacillus helveticus strain preferably has a high extracellular proteinase activity.
- Yamamoto et al. Yamamoto, N. et al. J. Biochem. (1993) 114, 740
- Twining et al. Twining, S. Anal. Biochem. 143 3410 (1984)
- a strain showing a value of UZOD590 of 00 or more is preferable. Lactobacillus helveticus strains having mycological properties can be used.
- Morphological properties 1) Cell shape; Neisseria gonorrhoeae, 2) Motility; None, 3) Presence or absence of spores; None, 4) Gram stainability;
- Physiological properties 1) Catalase; negative, 2) Indole formation; Negative, 3) Nitrate reduction; Negative, 4) Attitude toward oxygen; Facultative anaerobic bacteria, 5) DL by homolactic fermentation with glucose 1) Lactic acid is produced and no gas is produced.
- Examples of the preferred Lactobacillus helveticus include, for example, Lactobacillus helveticas CM4 strain (National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center, Tsukuba Sakaihigashi, Ibaraki, Japan 1 1 1 No .: FERM BP-6060, date of deposit August 15, 1997) (hereinafter referred to as CM4 strain).
- CM4 strain National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center, Tsukuba Sakaihigashi, Ibaraki, Japan 1 1 1 No .: FERM BP-6060, date of deposit August 15, 1997)
- This CM4 strain is registered with the above deposit number in the Budapest Treaty on the International Approval of Deposits for Microorganisms in Patent Procedures, and this strain has already been patented.
- the fermented milk whey can be obtained by adding a fermented milk starter containing the lactic acid bacterium to milk and appropriately selecting fermentation conditions such as a fermentation temperature for fermentation.
- Fermented milk whey which is an active ingredient, can be obtained by separating whey from the obtained fermented milk by conventional separation operations such as centrifugation and filtration.
- the separated whey can be appropriately fractionated, concentrated, purified, etc., and the whey or its concentrate can be used as a powder by freeze drying, spray drying or the like.
- the lactic acid bacterium is pre-cultured and used as a starter having a sufficiently high activity.
- the initial bacterial count is preferably about 10 5 to 10 9 cells / ml.
- yeast can be used in combination with the lactic acid bacteria.
- the species of yeast is not particularly limited, but preferred examples include yeasts of the genus Saccharomyces such as Saccharomyces cerevisiae.
- the content ratio of yeast can be appropriately selected according to the purpose.
- Examples of the raw milk include animal milk such as cow's milk, horse milk, sheep milk and goat milk, and plant milk such as soy milk, skim milk, reduced milk, powdered milk, condensed milk and the like that are processed milk thereof. Milk, soy milk, milk that is preferable to these processed milk or processed milk thereof is particularly preferable.
- the solids concentration of milk is not particularly limited. For example, when skim milk is used, the nonfat milk solids concentration is usually about 3 to 15% by weight, and 6 to 15% by weight is preferable in terms of productivity. .
- the fermentation is usually carried out by standing or stirring culture, for example, fermentation temperature 25 to 45 ° C, preferably 30 to 45 ° C, fermentation time 3 to 72 hours, preferably 12 to 36 hours. This can be done by stopping the fermentation when the acidity reaches 1.5 or higher.
- the epidermal cell differentiation and keratinization promoter of the present invention may contain other known epidermal cell fractions and known keratinization promoting components in addition to the fermented milk whey that is the active ingredient. Furthermore, various additives such as excipients may be included depending on the form. Since the essential active ingredient of the epidermal cell differentiation and keratinization promoting agent of the present invention is the fermented milk whey, the oral intake may have a desired effect depending on the administration period and its continuity. The force that can be selected as appropriate Usually, the amount of fermented milk whey is about 1 to 1000 mlZ human per day, preferably about 10 to 200 mlZ human.
- Administration of the epidermal cell fraction and the keratinization promoting agent of the present invention may be carried out daily even after symptoms due to skin keratinization have occurred, or continuously in a time to prevent such symptoms, or Can be taken intermittently.
- the functional food and drink of the present invention are foods and beverages containing the epidermal cell differentiation and keratinization promoter of the present invention, and have appealed for prevention and improvement related to the promotion of epidermal keratinization, for example, for specific health use It can be a food, a functional food or drink that displays an effect for promoting skin keratinization.
- Additives such as sugars, proteins, lipids, vitamins, minerals, flavors, or mixtures thereof may be added to the functional food and drink.
- fermented milk whey It may contain milk components other than whey before release.
- the blending ratio of the epidermal cell differentiation and keratinization promoter of the present invention can be appropriately selected according to the form and type of the food / beverage product, and the functional food / beverage product is continuously consumed.
- the fermented milk whey which is an active ingredient, is usually in the range of 0.1 to 100% by weight, preferably 10 to 90% by weight.
- Examples of the functional foods and drinks include, for example, fermented milk products such as yogurt and lactic acid bacteria beverages, various processed foods and drinks blended with fermented milk whey or concentrates thereof, dry powders, tablets, capsules, granules, etc. Is mentioned.
- the functional food and drink of the present invention is not particularly limited in terms of dosage and administration timing, but it is preferable to take it at about the dosage of the active ingredient. For example, it promotes keratinization of the skin. It can be ingested continuously or intermittently before contact with the necessary environment, etc., or after contact with such environment.
- Fermented milk was obtained by inoculating 3% CM4 strain starter (bacterial count 5 X 10 8 ZmL) in a milk medium with a solid content of 9% non-fat dry milk and fermenting at 37 ° C for 24 hours. . This fermented milk was centrifuged at 12000G for 20 minutes to remove the precipitate, and fermented milk whey was prepared. The following tests were performed using the obtained fermented milk whey.
- a is the expression observation result of KeratinlO without fermented milk whey
- b is the observation result of KeratinlO expression when fermented milk whey is added at a final concentration of 1%
- c is the addition of fermented milk whey
- d shows the observation result of Involucrin expression when fermented milk whey was added at a final concentration of 1%.
- RNAlng For the extracted total RNAlng, using the Smart Cycler II System (Cepheid), the One Step SYBR RT-PCR Kit (trade name, TaKaRa) and the primers shown in Table 1, and according to the protocol, ReaH: ime RT -PCR was performed to quantify the amount of keratin 10 (KeratinlO) mRNA, involucrin mRNA, and glyceraldehyde 3-phosphate dehydrogenase (GAPD) mRNA. The expression level is determined by dividing by the expression level of GAPD mRNA that is expected to be expressed in the same amount in any cell, and the value is defined as 0% of the fermented milk whey concentration in the medium in (b) above.
- KeratinlO keratin 10
- GAPD glyceraldehyde 3-phosphate dehydrogenase
- GAPDH 5 'primer GCACCGTCAAGGCTGAGAAC
- fermented milk whey promotes the expression of KeratinlO and Involucrin, which are differentiation markers in epidermal cells.
- Example 1 In order to facilitate the drinking of the fermented milk whey prepared in Example 1, 90 parts by weight of the fermented milk whey, 0.25 parts by weight of fragrance, 0.05 parts by weight of aspartame, and 9.70 parts by weight of water were mixed. A fermented milk whey-containing beverage was prepared. The following evaluation was performed using the obtained beverage: o
- the outermost stratum corneum cells were detached and transferred to a slide glass and fixed. These were each stained with brilliant green 'gentian nano violet (BG), and the stained images were taken into a computer. The stratum corneum cell area was measured by image analysis of the BG-stained image.
- BG brilliant green 'gentian nano violet
- the evaluation test was conducted on 16 male panels with an average age of 29.4 years, from 24 to 43 years. First, it was carried out before drinking the sample, and the average value of each panel was determined. Next, the fermented milk whey-containing beverage was drunk daily at 150 g for 9 weeks, and the evaluation test was performed again in the same manner in the 9th week to determine the average value of each panel. The results are shown in Table 2.
- Table 2 shows that the cell area of the group containing fermented milk whey-containing beverages increased 27 in 9 weeks of drinking, suggesting that long-term drinking of fermented milk whey-containing beverages promotes keratinization of the skin epidermis. It was done.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200800124A EA013926B1 (ru) | 2005-06-24 | 2006-06-23 | Промотор дифференциации и кератинизации эпидермальной клетки и функциональный напиток/питание для ускорения кератинизации эпидермиса |
CN200680030360XA CN101242849B (zh) | 2005-06-24 | 2006-06-23 | 表皮细胞分化和角化促进剂、以及用于促进表皮角化的功能性饮料食品 |
CA002614111A CA2614111A1 (en) | 2005-06-24 | 2006-06-23 | Promoter of differentiation and keratinization of epidermic cell and functional beverage/food for promotion of keratinization of epidermis |
EP06767228.7A EP1902720B1 (en) | 2005-06-24 | 2006-06-23 | Fermented milk whey for an oral use in improving symptoms of atopic dermatitis, xeroderma or psoriasis. |
JP2007522377A JP5160889B2 (ja) | 2005-06-24 | 2006-06-23 | 表皮細胞分化及び角化促進剤 |
US11/993,111 US8097246B2 (en) | 2005-06-24 | 2006-06-23 | Promoter of differentiation and keratinization of epidermic cell and functional beverage/food for promotion of keratinization of epidermis |
AU2006260100A AU2006260100A1 (en) | 2005-06-24 | 2006-06-23 | Promoter of differentiation and keratinization of epidermic cell and functional beverage/food for promotion of keratinization of epidermis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005184994 | 2005-06-24 | ||
JP2005-184994 | 2005-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006137513A1 true WO2006137513A1 (ja) | 2006-12-28 |
Family
ID=37570530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/312578 WO2006137513A1 (ja) | 2005-06-24 | 2006-06-23 | 表皮細胞分化及び角化促進剤、並びに表皮角化促進用機能性飲食品 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8097246B2 (ja) |
EP (1) | EP1902720B1 (ja) |
JP (1) | JP5160889B2 (ja) |
KR (1) | KR20080019059A (ja) |
CN (1) | CN101242849B (ja) |
AU (1) | AU2006260100A1 (ja) |
CA (1) | CA2614111A1 (ja) |
EA (1) | EA013926B1 (ja) |
TW (1) | TW200740378A (ja) |
WO (1) | WO2006137513A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000875A3 (en) * | 2007-06-27 | 2009-12-23 | Chr. Hansen A/S | Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis |
WO2010071132A1 (ja) | 2008-12-15 | 2010-06-24 | カルピス株式会社 | 皮膚老化抑制ペプチド |
KR20170020720A (ko) | 2014-06-26 | 2017-02-23 | 니폰 제온 가부시키가이샤 | 배양 세포의 분화 촉진 방법 및 배양 세포 분화 촉진제 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2340803A1 (en) * | 2009-12-30 | 2011-07-06 | Brands Asia Pacific Limited | Dead skin exfoliating composition and pad for hands and feet |
EP2465507A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating skin diseases |
KR101998210B1 (ko) * | 2012-10-31 | 2019-07-10 | (주)아모레퍼시픽 | 녹차 유산균을 포함하는 피부 각질 제거용 조성물 |
SG11201509599QA (en) * | 2013-07-05 | 2016-02-26 | Yakult Honsha Kk | Pentosidine production inhibitor |
WO2019158652A1 (fr) * | 2018-02-14 | 2019-08-22 | Danstar Ferment Ag | Composition cosmetique ou dermatologique et methode pour l'hydratation cutanee |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1045610A (ja) * | 1996-08-07 | 1998-02-17 | Karupisu Kk | 抗ストレス剤及び抗ストレス作用を有する機能性食品 |
JPH1198978A (ja) * | 1997-09-26 | 1999-04-13 | The Calpis Co Ltd | トリペプチド高生産性ラクトバチルス・ヘルベチカス乳酸菌 |
JP2000239175A (ja) * | 1999-02-18 | 2000-09-05 | Calpis Co Ltd | 抗アレルギー剤 |
JP3227378B2 (ja) | 1996-03-29 | 2001-11-12 | カネボウ株式会社 | 表皮角質化促進剤 |
JP2002241289A (ja) * | 2001-02-16 | 2002-08-28 | Ichimaru Pharcos Co Ltd | 肥厚化角質層柔軟化剤 |
JP2004501199A (ja) * | 2000-06-28 | 2004-01-15 | セリカウサ ベーヴェー | 異化乳清から成るまたは少なくとも異化乳清を含む組成物の使用 |
JP2004510740A (ja) * | 2000-10-06 | 2004-04-08 | ソシエテ デ プロデュイ ネスレ ソシエテ アノニム | 皮膚の免疫系のバランスを保つためのプロバイオティック乳酸菌の使用 |
JP2005206578A (ja) * | 2003-12-25 | 2005-08-04 | Calpis Co Ltd | 経口摂取用保湿剤及び機能性飲食品 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2826808B2 (ja) * | 1995-07-14 | 1998-11-18 | カルピス株式会社 | 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品 |
-
2006
- 2006-06-23 WO PCT/JP2006/312578 patent/WO2006137513A1/ja active Application Filing
- 2006-06-23 TW TW095122776A patent/TW200740378A/zh unknown
- 2006-06-23 US US11/993,111 patent/US8097246B2/en not_active Expired - Fee Related
- 2006-06-23 KR KR1020087000629A patent/KR20080019059A/ko not_active Application Discontinuation
- 2006-06-23 JP JP2007522377A patent/JP5160889B2/ja active Active
- 2006-06-23 CA CA002614111A patent/CA2614111A1/en not_active Abandoned
- 2006-06-23 EA EA200800124A patent/EA013926B1/ru not_active IP Right Cessation
- 2006-06-23 CN CN200680030360XA patent/CN101242849B/zh not_active Expired - Fee Related
- 2006-06-23 EP EP06767228.7A patent/EP1902720B1/en active Active
- 2006-06-23 AU AU2006260100A patent/AU2006260100A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3227378B2 (ja) | 1996-03-29 | 2001-11-12 | カネボウ株式会社 | 表皮角質化促進剤 |
JPH1045610A (ja) * | 1996-08-07 | 1998-02-17 | Karupisu Kk | 抗ストレス剤及び抗ストレス作用を有する機能性食品 |
JPH1198978A (ja) * | 1997-09-26 | 1999-04-13 | The Calpis Co Ltd | トリペプチド高生産性ラクトバチルス・ヘルベチカス乳酸菌 |
JP2000239175A (ja) * | 1999-02-18 | 2000-09-05 | Calpis Co Ltd | 抗アレルギー剤 |
JP2004501199A (ja) * | 2000-06-28 | 2004-01-15 | セリカウサ ベーヴェー | 異化乳清から成るまたは少なくとも異化乳清を含む組成物の使用 |
JP2004510740A (ja) * | 2000-10-06 | 2004-04-08 | ソシエテ デ プロデュイ ネスレ ソシエテ アノニム | 皮膚の免疫系のバランスを保つためのプロバイオティック乳酸菌の使用 |
JP2002241289A (ja) * | 2001-02-16 | 2002-08-28 | Ichimaru Pharcos Co Ltd | 肥厚化角質層柔軟化剤 |
JP2005206578A (ja) * | 2003-12-25 | 2005-08-04 | Calpis Co Ltd | 経口摂取用保湿剤及び機能性飲食品 |
Non-Patent Citations (6)
Title |
---|
"International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology", TSUKUBA CENTRAL, vol. 6, no. 1, pages 1 - 1 |
ARAKATSU S.: "Nyusankin o Riyoshita Kinosei Keshohin Shokuhin no Kaihatsu Kenkyu Doko", FOODS & FOD INGREDIENTS JOURNAL OF JAPAN, vol. 209, no. 9, 2004, pages 780 - 792, XP003007238 * |
BAUMGARTNER M. ET AL.: "CONTROLLED TRIALS INVESTIGATING THE USE OF ONE PARTIALLY HYDROLYZED WHEY FORMULA FOR DIETARY PREVENTION OF ATOPIC MANIFESTATIONS UNTIL 60 MONTHS OF AGE: AN OVERVIEW USING META-ANALYTICAL TECHNIQUES", NUTRITION RESEARCH, vol. 18, no. 8, 1998, pages 1425 - 1442, XP003007239 * |
See also references of EP1902720A4 |
TWINING, S., ANAL. BIOCHEM., vol. 143, 1984, pages 3410 |
YAMAMOTO N. ET AL., BIOCHEM., vol. 114, 1993, pages 740 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000875A3 (en) * | 2007-06-27 | 2009-12-23 | Chr. Hansen A/S | Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis |
WO2010071132A1 (ja) | 2008-12-15 | 2010-06-24 | カルピス株式会社 | 皮膚老化抑制ペプチド |
US9067972B2 (en) | 2008-12-15 | 2015-06-30 | Calpis Co., Ltd. | Skin aging-inhibiting peptide |
KR20170020720A (ko) | 2014-06-26 | 2017-02-23 | 니폰 제온 가부시키가이샤 | 배양 세포의 분화 촉진 방법 및 배양 세포 분화 촉진제 |
Also Published As
Publication number | Publication date |
---|---|
EP1902720A4 (en) | 2012-03-28 |
CN101242849B (zh) | 2011-07-27 |
KR20080019059A (ko) | 2008-02-29 |
AU2006260100A1 (en) | 2006-12-28 |
CA2614111A1 (en) | 2006-12-28 |
JP5160889B2 (ja) | 2013-03-13 |
EA013926B1 (ru) | 2010-08-30 |
US8097246B2 (en) | 2012-01-17 |
JPWO2006137513A1 (ja) | 2009-01-22 |
EP1902720B1 (en) | 2014-09-17 |
EP1902720A1 (en) | 2008-03-26 |
CN101242849A (zh) | 2008-08-13 |
US20100166877A1 (en) | 2010-07-01 |
EA200800124A1 (ru) | 2008-06-30 |
TW200740378A (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5160889B2 (ja) | 表皮細胞分化及び角化促進剤 | |
US7244425B2 (en) | Acid- and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol | |
WO2008114503A1 (en) | Composition for improving intestinal microflora | |
KR102368627B1 (ko) | 지방 축적 억제용 조성물 | |
WO2013107913A1 (en) | Gaba-producing culturable bacteria derived from the human gastrointestinal tract | |
TW200817508A (en) | Lactic acid bacterium for amelioration of lactose intolerance | |
JPWO2018003899A1 (ja) | 腎性貧血改善用組成物 | |
KR102368628B1 (ko) | Iv형 알레르기용 조성물 | |
CN110835615B (zh) | 乳双歧杆菌gkk2的活性物质、含其的组合物及其促进长寿的用途 | |
JP4680571B2 (ja) | 経口摂取用保湿剤 | |
KR102368626B1 (ko) | I형 알레르기용 조성물 | |
JPWO2018003898A1 (ja) | 軟骨再生促進用組成物 | |
CN117165497B (zh) | 一种改善便秘的植物乳植杆菌Lp18及其应用和产品 | |
WO2006095764A1 (ja) | 皮膚における紫外線感受性抑制剤及び機能性飲食品 | |
Cano et al. | Demonstration of the cellular viability and safety of Enterococcus faecium CRL 183 in long-term experiments | |
JP2021101645A (ja) | 免疫バランスの調節のための組成物 | |
CN117645941A (zh) | 一种通过同时降解尿酸和嘌呤核苷缓解高尿酸血症的发酵粘液乳杆菌及其应用 | |
CN117917475A (zh) | 一种调节肠道菌群的植物乳植杆菌p16及其应用、产品和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680030360.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2614111 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007522377 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087000629 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006767228 Country of ref document: EP Ref document number: 2006260100 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200800124 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2006260100 Country of ref document: AU Date of ref document: 20060623 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11993111 Country of ref document: US |